Creative Biolabs, one of the industry-pioneering CROs holding specialties in bioconjugate, participated in the 13th Annual World ADC Summit last week and announced the successful accomplishment of its journey in San Diego.
The field of antibody-drug conjugate (ADC) has ushered in an era of explosive progress when huge breakthroughs emerge every now and then. Creative Biolabs, as one of the industry-pioneering contract research organizations specializing in ADC development, participated in the unprecedentedly prosperous event ever in the ADC community—the 13th World ADC San Diego 2022, showcasing the exclusive solutions for ADC R&D and first-rate ADC products meanwhile seeking strategic partnerships.
“The World ADC San Diego 2022 is a grand affair,” according to one of the delegates from Creative Biolabs, “bridging a platform for researchers and service providers to share views and the most recent breakthroughs and talk about new projects through round table meetings and scientific sessions, and we are happy to have so many experts stop by our booth these days, hoping they were having fun with the app gamification and the small gifts we prepared.”
Creative Biolabs has been diving into synthetic chemistry and antibody areas since its setup, which has established a thoroughgoing one-stop service workflow to support global customers’ diverse bioconjugate projects involving antibody-drug conjugate, antibody-antibiotic conjugate, antibody-enzyme conjugate, and particularly bispecific antibody-drug conjugate that is at the eye of the storm.
“During the two-day exhibition, we not only presented the exclusive solutions, but also highlighted our industry-acclaimed products,” said the delegate “which were carefully prepared under strict QC systems and can quickly join the projects of our customers, including customized ADCs, ADC toxins, linkers, and drug-linker complexes.”
With offices across continents, Creative Biolabs has exclusive access to a tremendous pool of resources and keeps on exploring to enlarge its service and product coverage. Hopefully, the company will also participate in this ADC affair next year.
“We have many exhibitions on our calendar,” added the delegate “as we’re glad to see in-person events are back on the stage, which are perfect chances for CROs like us to talk face to face about the new projects, technological advancements and join with the community to develop innovative conjugates for therapeutics improvement.”